Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of 28 day oral
administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE).
The secondary objectives are to examine the effect of BAY85-8501 on pulmonary function,
biomarkers of inflammation and tissue damage, and the impact on overall health and perceived
well-being and to evaluate the pharmacokinetics of BAY85-8501.